Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genes and compounds that increase type VII collagen expression as potential treatments for dystrophic epidermolysis bullosa.

Experimental dermatology - 1 Jul 2022

Thompson Elizabeth L, Pickett-Leonard Michael, Riddle Megan J, Chen Weili, Albert Frank W, Tolar Jakub

Abstract excerpt

Dystrophic epidermolysis bullosa (DEB) is a skin-blistering disease caused by mutations in COL7A1, which encodes type VII collagen (C7). There is no cure for DEB, but previous work has shown potential therapeutic benefit of increased production of even partially functional C7. Genome-wide screens using CRISPR-Cas9 have enabled the identification of genes involved in cancer development, drug resistance and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Collagen Type VII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermolysis Bullosa Dystrophica

Share to Keratinocytes

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35243691
DOI: 10.1111/exd.14555
PMCID: PMC9318024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genes and compounds that increase type VII collagen expression as potential treatments for dystrophic epidermolysis bullosa.PMID 35243691Read ↗

CRISPR/Cas9-mediated Generation of <i>COL7A1</i> -deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Gene Therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

TALEN-based gene correction for epidermolysis bullosa.Semantic proximity Read ↗

A Novel Fluorescence-Based Screen of Gene Editing Molecules for Junctional Epidermolysis Bullosa.Semantic proximity Read ↗

Predictable CRISPR/Cas9-Mediated COL7A1 Reframing for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.Semantic proximity Read ↗

Therapies for genetic extracellular matrix diseases of the skin.Semantic proximity Read ↗

Generation of the induced pluripotent stem cell line (ZSPHARi001-A) from a patient with recessive dystrophic epidermolysis bullosa carrying compound heterozygous mutation in the COL7A1 gene.Semantic proximity Read ↗

A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.